Title

Human fetal neural precursor cells can up-regulate MHC class I and class IIexpression and elicit CD4 and CD8 T cell proliferation

Document Type

Journal Article

Publisher

Elsevier Inc

Faculty

Computing, Health and Science

School

Exercise, Biomedical & Health Science

RAS ID

10777

Comments

This article was originally published as: Goya, R., Busch, R., Mathur, R., Coles, A., & Barker, R. (2010). Human fetal neural precursor cells can up-regulate MHC class I and class II expression and elicit CD4 and CD8 T cell proliferation. Neurobiology of Disease, 41(2), 407-414. Original article available here

Abstract

The use of allogeneic fetal neural precursor cells (NPCs) as a cell replacement therapy in neurodegenerative disorders holds great promise. However, previous studies concerning the possibility of alloimmune rejection of the transplanted cells have been inconclusive. Here, we used flow cytometry to quantify the expression of major histocompatibility complex (MHC) molecules by human NPCs, obtained from the cortex or ventral mesencephalon of fetuses with gestational ages between 7 and 11 weeks. MHC class I was undetectable on the surface of freshly isolated primary fetal tissue from either location, but increased over time in proliferating NPC cultures; after 7 days in vitro, MHC class I was detectable on most cells. Following differentiation, MHC class I expression persisted on non-neuronal cells. MHC class II levels remained low at all time points but were inducible by pro-inflammatory cytokines, whereas the co-stimulatory molecules, CD80 and CD86, remained undetectable. Nonetheless, CD4+ and CD8+ T cells proliferated when peripheral blood mononuclear cells (PBMCs) were cultured with allogeneic NPCs. Weaker responses were obtained when NPCs were co-cultured with purified allogeneic responder T cells, suggesting that indirect allorecognition contributed significantly to PBMC responses. In conclusion, differentiating human NPCs are immunogenic in vitro, suggesting that they may trigger immune rejection unless transplant recipients are immunosuppressed.

DOI

10.1016/j.nbd.2010.10.008

 

Link to publisher version (DOI)

10.1016/j.nbd.2010.10.008